By Natalie Grover (SOURCE)

Successful late-stage data on Shire Plc’s, long-acting preventative treatment for hereditary angioedema (HAE) brings the Dublin-based drugmaker one step closer to U.S. approval, it said on Thursday.

U.S.-listed shares of the rare disease drugmaker, which already sells several HAE treatments, were up about 3.4 percent at $188.23 in late-morning trading.

The drug, lanadelumab, which is expected to generate more than $2 billion in peak sales will help Shire protect and grow its existing HAE franchise, which accounts for about 10 percent of its profit, analysts said.

Patients with HAE suffer from recurrent episodes of severe swelling, typically in the extremities, gastrointestinal tract and upper airways. It affects about one in 50,000 people, according to the U.S. National Institutes of Health.

Existing treatments in the United States are either injections for acute attacks or short-acting intravenous infusions administered twice a week.

In Shire’s late-stage study, three dosing arms of lanadelumab (150 or 300 mg every four weeks or 300 mg every two weeks) were tested against a placebo in 125 patients.

Treatment with the drug induced a statistically significant reduction in attacks across all regimens, regardless of baseline attack rate, Shire said.

In particular, the 300 mg dose reduced the monthly attack rate by 87 percent versus a placebo when given every two weeks. 

Data also showed that a significantly higher proportion of patients on lanadelumab were attack free for the 26-week study. 

Given lanadelumab’s compelling efficacy and advantage over existing treatments, Deutsche Bank analysts said they expected it to dominate and significantly expand the current $1.8 billion HAE prophylaxis market. 

The U.S. Food and Drug Administration has already granted the drug – which Shire acquired through its $5.9 billion buyout of Dyax in 2016 – “orphan drug” and “breakthrough therapy” designations.

Shire said it planned to submit a U.S. marketing application for lanadelumab by late 2017/early 2018. The company also expects to submit an EU application in the first half of next year, pending regulatory discussions.

On a conference call with analysts, Shire said it was still analyzing the dataset and did not provide any clarity on pricing.

Shire’s existing HAE drugs include Kalbitor, Cinryze and Firazyr. Other FDA-approved treatments include CSL Behring’s Berinert and Valeant Pharmaceuticals International Inc’s, Ruconest.

Shire’s UK-listed shares were up 1.7 percent at 4814.5 pence.

Shares of U.S. drugmaker BioCryst Pharmaceuticals Inc, which is developing an oral HAE drug, were up about 6 percent.

(Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty and Martina D’Couto)

164 thoughts on “Shire’s Swelling Disorder Drug Moves Closer to U.S. Approval”

  1. Pingback: lasix renogram
  2. Pingback: xenical 120mg uk
  3. Pingback: bimatoprost lcms
  4. Pingback: domperidone msds
  5. Pingback: valacyclovir dog
  6. Pingback: cialis sales
  7. Pingback: Google
  8. Pingback: what cialis does
  9. Pingback: virectin vs viagra
  10. Pingback: Google
  11. Pingback: viagra pills
  12. Pingback: Kidney Infection
  13. Pingback: male sex toys
  14. Pingback: zeytinburnu escort
  15. Pingback: sports
  16. Pingback: happyluke
  17. Pingback: happyluke
  18. Pingback: ucuz escort
  19. Pingback: maltepe escort
  20. Pingback: happyluke
  21. Pingback: thrusting rabbit
  22. Pingback: mersin escort
  23. Pingback: Takeout Food
  24. Pingback: fun88
  25. Pingback: prostate milking
  26. Pingback: rabbit vibrator
  27. Pingback: best vagina pump
  28. Pingback: about
  29. Pingback: MILF Porn
  30. Pingback: ground leases
  31. Pingback: lotto vip
  32. Pingback: huay
  33. Pingback: huge dildo review
  34. Pingback: Dank Cartridges
  35. Pingback: sultangazi escort
  36. Pingback: 99defi Blockchain
  37. Pingback: vehicle movements
  38. Pingback: site de streaming
  39. Pingback: french streaming
  40. Pingback: french streaming
  41. Pingback: Here
  42. Pingback: best sex toys
  43. Pingback: male masturbator
  44. Pingback: petit school
  45. Pingback: 안전놀이터
  46. Pingback: 머니상
  47. Pingback: stromectol 6 price
  48. Pingback: Thc oil cartridge
  49. Pingback: mr proper
  50. Pingback: BUY MESCALINE
  51. Pingback: Holyhead School
  52. Pingback: mp3juices
  53. Pingback: Referencement web
  54. Pingback: Maasai tribe kenya
  55. Pingback: best male sex toys
  56. Pingback: aromatherapy oils
  57. Pingback: ivermectin 6 uses
  58. Pingback: web development
  59. Pingback: sig p320x carry
  60. Pingback: magic mushrooms
  61. Pingback: magic mushrooms
  62. Pingback: juul pods for sale
  63. Pingback: pallas cat
  64. Pingback: Thc vape oil
  65. Pingback: Travelmonke Tours
X